NCT01779206View on ClinicalTrials.gov

ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

4,936

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

September 30, 2019

Study Completion Date

January 15, 2025

Conditions

Breast Cancer

Interventions

DRUG

Epirubicin

DRUG

Cyclophosphamide

DRUG

Docetaxel

DRUG

Paclitaxel

Trial Locations (2)

41061

Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, Mönchengladbach

81377

Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern, Munich

All Listed Sponsors

lead

West German Study Group

OTHER

NCT01779206 - ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer | Biotech Hunter | Biotech Hunter